5 completed, 1 recruiting, 1 withdrawn. 7 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 5, Recruiting 1, Withdrawn 1 |
| Phase 2 | 4 | Completed 2, Recruiting 1, Withdrawn 1 |
Follow Primary Hyperparathyroidism: new trials by email Literature Review of Primary Hyperparathyroidism trials Research Report on Primary Hyperparathyroidism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors 18F-FCH, NeuroEXPLORER - Primary Hyperparathyroidism, Parathyroid Cancer | Phase 2 / Phase 3 | Recruiting | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 193 | 2026-04-16 | 2026-10-29 |
| Phase 3 Study of KHK7580 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Primary Hyperparathyroidism KHK7580 - Parathyroid Carcinoma, Primary Hyperparathyroidism | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 18 | 2017-08-30 | 2021-05-27 |
| Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet. Cinacalcet 30 mg Tablet, Denosumab Inj 60 mg/ml, Placebo tablets - Primary Hyperparathyroidism, Parathyroid Adenoma | Phase 3 | Completed | Peter Vestergaard | 46 | 2017-03-01 | 2021-05-25 |
| Evaluating Alternative Medical Therapies in Primary Hyperparathyroidism eplerenone, amiloride, Placebo - Primary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | Brigham and Women's Hospital | 69 | 2016-01-01 | 2023-05-03 |
| An Intra-individual Titration Study of KRN1493 for the Treatment of Hypercalcemia in Patients With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism Cinacalcet HCl - Parathyroid Carcinoma, Hypercalcemia | Phase 3 | Completed | Kyowa Kirin Co., Ltd. | 2011-11-01 | 2017-03-03 | |
| Primary Hyperparathyroidism (PHPT): Early Effect of Vitamin D Placebo, Vitamin D3 - Primary Hyperparathyroidism, Hypercalcemia | Phase 2 / Phase 3 | Withdrawn | Columbia University | 2010-05-01 | 2015-03-05 | |
| Effect of Vitamin D Treatment in Primary Hyperparathyroidism Cholecalciferol - Vitamin D Deficiency, Primary Hyperparathyroidism | Phase 2 / Phase 3 | Completed | University of Aarhus | 46 | 2008-05-01 | 2013-11-18 |
Hyperparathyroidism, Primary (7) · Parathyroid Neoplasms (4) · Hypercalcemia (3) · Vitamin D Deficiency (2) · Bone Diseases, Metabolic (1) · Multiple Endocrine Neoplasia Type 1 (1) · Osteoporosis (1)
Endocrine System Diseases (7) · Hyperparathyroidism (7) · Parathyroid Diseases (7) · Endocrine Gland Neoplasms (4) · Head and Neck Neoplasms (4) · Neoplasms (4) · Neoplasms by Site (4) · Calcium Metabolism Disorders (3) · Metabolic Diseases (3) · Nutritional and Metabolic Diseases (3) · Water-Electrolyte Imbalance (3) · Avitaminosis (2) · Deficiency Diseases (2) · Malnutrition (2) · Nutrition Disorders (2)
Cinacalcet (3) · Cholecalciferol (2) · Amiloride (1) · Denosumab (1) · Eplerenone (1) · Sodium Chloride (1) · Tablets (1) · Vitamin D (1) · evocalcet (1) · fluorocholine (1)
Kyowa Kirin Co., Ltd. (2) · Brigham and Women's Hospital (1) · Columbia University (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Peter Vestergaard (1) · University of Aarhus (1)
United States (3) · Denmark (2) · Japan (2)
Anand Vaidya, MD MMSc (1) · Julius Simoni Leere, MD (1) · Lars Rejnmark, MD,PhD,DrMed (1) · Lars Rolighed, MD (1) · Peter Vestergaard, DMSc (1) · Shonni J. Silverberg, MD (1) · Smita Jha, M.D. (1)
2016 (1), R01DK084986 (1)